Skip to main content
    O

    Ocular Therapeutix Inc (OCUL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.38
    +0.18 (+2.50%)

    Market Cap: $1.58B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    31%(12/39)
    Avg Surprise
    -25.64%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.37 - $-0.30
    5 analysts
    EPS Revisions
    4
    0
    7d
    4
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.39+9.2%
    60d ago$-0.39+9.2%
    30d ago$-0.350.0%
    7d ago$-0.350.0%
    Current$-0.35
    Revenue Consensus
    $14M
    Range$13M - $16M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.37
    Range$-0.48 - $-0.12
    4 analysts
    Revenue Consensus
    $13M
    Range$11M - $16M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.37---
    Sep 26EST
    		-$-0.35---
    Jun 26
    Reported Aug 3
    		$-0.35$-0.40+12.50%Beat+10.3%
    Mar 26
    Reported May 5
    		$-0.40$-0.31-29.03%Miss-8.1%
    Dec 25
    Reported Feb 5
    		$-0.29$-0.34+14.71%Beat+0.0%
    Sep 25
    Reported Nov 4
    		$-0.38$-0.35-8.57%Miss-72.7%
    Jun 25
    Reported Aug 5
    		$-0.39$-0.35-11.43%Miss-50.0%
    Mar 25
    Reported May 5
    		$-0.37$-0.28-32.14%Miss-54.2%
    Dec 24
    Reported Mar 3
    		$-0.29$-0.22-31.82%Miss+17.1%
    Sep 24
    Reported Nov 14
    		$-0.22$-0.21-4.76%Miss-15.8%
    Jun 24
    Reported Aug 7
    		$-0.26$-0.21-23.81%Miss+0.0%
    Mar 24
    Reported May 7
    		$-0.24$-0.18-33.33%Miss+22.6%
    Dec 23
    Reported Mar 11
    		$-0.35$-0.30-16.67%Miss-45.8%
    Sep 23
    Reported Nov 7
    		$-0.19$-0.25+24.00%Beat+36.7%
    Jun 23
    Reported Aug 7
    		$-0.26$-0.29+10.34%Beat-23.8%
    Mar 23
    Reported May 8
    		$-0.31$-0.24-29.17%Miss-24.0%
    Dec 22
    Reported Mar 6
    		$-0.24$-0.25+4.00%Beat-380.0%
    Sep 22
    Reported Nov 7
    		$-0.30$-0.21-42.86%Miss-7.1%
    Jun 22
    Reported Aug 8
    		$-0.21$-0.18-16.67%Miss+27.6%
    Mar 22
    Reported May 9
    		$-0.25$-0.22-13.64%Miss+13.8%
    Dec 21
    Reported Feb 28
    		$-0.05N/A+78.26%Beat+95.9%
    Sep 21
    Reported Nov 8
    		$-0.28$-0.26-7.69%Miss-47.4%
    Jun 21
    Reported Aug 9
    		$-0.29$-0.21-38.10%Miss+54.7%
    Mar 21
    Reported May 5
    		$-0.29$-0.21-38.10%Miss+29.3%
    Dec 20
    Reported Mar 11
    		$-1.21$-0.17-611.76%Miss-128.3%
    Sep 20
    Reported Nov 5
    		$-0.19$-0.25+24.00%Beat+57.8%
    Jun 20
    Reported Aug 7
    		$-0.64$-0.32-100.00%Miss-12.3%
    Mar 20
    Reported May 8
    		$-0.41$-0.49+16.33%Beat+14.6%
    Dec 19
    Reported Mar 12
    		$-0.53$-0.45-17.78%Miss-26.2%
    Sep 19
    Reported Nov 12
    		$-0.45$-0.46+2.17%Beat-18.4%
    Jun 19
    Reported Aug 7
    		$-0.57$-0.48-18.75%Miss-54.1%
    Mar 19
    Reported May 10
    		$-0.48$-0.42-14.29%Miss-20.0%
    Dec 18
    Reported Mar 7
    		$-0.42$-0.38-10.53%Miss+4.5%
    Sep 18
    Reported Nov 7
    		$-0.38$-0.37-2.70%Miss+29.6%
    Jun 18
    Reported Aug 7
    		$-0.37$-0.37+0.00%Beat+42.2%
    Mar 18
    Reported May 8
    		$-0.40$-0.41+2.44%Beat+31.0%
    Dec 17
    Reported Mar 8
    		$-0.44$-0.52+15.38%Beat+15.4%
    Sep 17
    Reported Nov 7
    		$-0.54$-0.53-1.89%Miss-
    Jun 17
    Reported Aug 8
    		$-0.64$-0.57-12.28%Miss-
    Mar 17
    Reported May 5
    		$-0.58$-0.48-20.83%Miss-
    Dec 16
    Reported Mar 10
    		$-0.52$-0.45-15.56%Miss-

    Key Metrics

    Valuation
    P/E Ratio-5.20EV/EBITDAN/A
    Price/FCF-6.51xFCF Yield-15.37%
    Profitability
    Profit Margin0.00%Operating Margin-609.00%
    ROE-73.00%ROIC-41.66%
    Financial Health
    Debt/Equity0.14xInterest Coverage-27.42x
    Current Ratio13.11xQuick Ratio13.03x
    Trading Statistics
    Beta0.99Avg Volume3.86M
    52-Week High$16.4452-Week Low$6.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.32
    SMA 20$8.18
    SMA 50$9.56
    SMA 200$9.37
    EMA 10$7.53
    EMA 20$8.08
    EMA 50$8.92
    EMA 200$9.51

    MACD

    Line: -0.72Signal: -0.72Hist: -0.00

    ADX

    ADX: 36.0+DI: 14.2-DI: 32.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down68.0
    PSAR$6.85

    Bollinger Bands

    Upper Band$10.66
    Lower Band$5.70
    %B Position6061%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    35.3

    Momentum Oscillators

    Stoch %K16.8
    Stoch %D16.9
    Williams %R-77.2
    ROC (10d)1.2%
    Momentum0.09
    CCI (20d)-53.7
    MFI (14d)24.6

    Volatility Measures

    ATR (14d)$0.50(6.8%)
    StdDev (20d)1.24
    Hist Vol86.5%(High)

    Volume Flow

    VWAP$7.36
    OBV-15.5M
    AD Line-18.9M
    CMF (20d)-0.219

    Volume Metrics

    Avg Vol (20d)4.0M
    Vol Ratio0.8x
    VWMA (20d)$7.92

    Pivot Points

    R3$7.54
    R2$7.42
    R1$7.31
    Pivot Point$7.19
    S1$7.08
    S2$6.96
    S3$6.85

    Advanced Oscillators

    TSI-33.65
    Ultimate Osc43.7
    KST-284.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$13.47M$10.79M$13.25M$14.54M$13.46M$10.70M$17.08M$15.43M$16.44M$14.77M$14.80M$15.08M
    Cost of Revenue$2.01M$1.33M$1.59M$1.77M$1.94M$1.26M$1.23M$1.56M$1.51M$1.33M$1.39M$1.38M
    Gross Profit$11.46M$9.46M$11.66M$12.77M$11.52M$9.44M$15.85M$13.86M$14.93M$13.45M$13.42M$13.70M
    Operating Expenses$93.57M$102.80M$81.42M$81.47M$79.16M$73.35M$66.43M$59.86M$58.52M$45.06M$33.47M$32.92M
    R&D$54.14M$66.21M$50.80M$52.36M$51.08M$42.86M$40.99M$37.05M$28.86M$20.73M$16.20M$15.02M
    SG&A$22.16M$20.01M$17.66M$16.02M$14.35M$16.35M$14.60M$12.23M$19.67M$14.15M$8.02M$8.58M
    Operating Income$-82,109,000$-93,340,000$-69,761,000$-68,698,000$-67,641,000$-63,917,000$-50,576,000$-45,998,000$-43,590,000$-31,617,000$-20,049,000$-19,214,000
    Interest Income$5.45M$6.05M$7.34M$3.73M$3.46M$3.83M$4.67M$5.65M$6.04M$3.92M$1.46M$1.21M
    Interest Expense$2.79M$2.78M$2.83M$3.00M$3.02M$2.98M$3.11M$3.22M$3.20M$32.00M$4.15M$-10,764,000
    Income Before Tax$-78,763,000$-88,612,000$-64,683,000$-69,418,000$-67,814,000$-64,053,000$-48,388,000$-36,493,000$-43,777,000$-64,848,000$-29,219,000$-516,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-78,763,000$-88,612,000$-64,654,000$-69,418,000$-67,814,000$-64,053,000$-48,388,000$-36,493,000$-43,777,000$-64,848,000$-29,220,000$-516,000
    EBITDA$-78,929,000$-89,221,000$-67,453,000$-68,318,000$-66,519,000$-62,478,000$-48,426,000$-37,342,000$-45,092,000$-33,881,000$-24,015,000$-9,530,000
    EBIT$-81,420,000$-91,885,000$-69,195,000$-70,145,000$-68,253,000$-64,895,000$-49,953,000$-38,922,000$-46,617,000$-36,769,000$-26,526,000$-12,492,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OCUL

    News

    Long term debt to total equity ratio of Ocular Therapeutix Inc – HAN:0OT

    The article provides financial data for Ocular Therapeutix Inc (HAN:0OT) on the Hannover Stock Exchange, specifically focusing on its long-term debt to total equity ratio. It indicates that the market was closed with no...

    TradingView•10/15/26•Neutral

    Form 4 Ocular Therapeutix Inc: Todd Anderman (CLO) For: 8 October

    This article reports on a Form 4 filing for Ocular Therapeutix Inc, specifically detailing a transaction by Todd Anderman, the company's Chief Legal Officer...

    Investing.com India•10/13/26•Neutral

    Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock By Investing.com

    Todd Anderman, Chief Legal Officer of Ocular Therapeutix (NASDAQ:OCUL), sold 11,984 shares totaling $87,363 to cover tax obligations from restricted stock unit vesting. Following these transactions...

    Investing.com India•10/13/26•Neutral

    Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock

    Ocular Therapeutix's Chief Legal Officer, Todd Anderman, sold 11,984 shares of the company's common stock for $87,363 on October 8...

    Investing.com•10/13/26•Neutral

    To cover vesting taxes, Ocular Therapeutix (OCUL) legal chief sold 11,984 shares.

    Ocular Therapeutix's Chief Legal Officer, Todd Anderman, sold 11,984 shares of common stock on October 8, 2026...

    Stock Titan•10/13/26•Neutral

    OCUL Valuation and Fair Value

    P/E
    -5.2x
    P/FCF
    -6.5x
    PEG
    0.0x
    P/B
    3.2x
    See GNG's fair value

    OCUL Profitability: Margins, ROIC and FCF

    Gross margin
    87.1%
    Operating margin
    -609.0%
    Net margin
    0.0%
    ROIC
    -41.7%
    ROE
    -73.0%
    FCF margin
    -490.1%
    FCF yield
    -15.4%

    OCUL Competitors

    CompanyTicker
    Kestra Medical Technologies, Ltd. Common StockKMTS
    Compass Pathways PlcCMPS
    Zenas BioPharma, Inc. Common StockZBIO
    RAPT Therapeutics IncRAPT
    Forte Biosciences IncFBRX
    Structure Therapeutics Inc. American Depositary SharesGPCR
    Omnicell IncOMCL
    Phibro Animal Health CorporationPAHC

    Sector: Healthcare

    OCUL Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    4
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    OCUL Bull Case vs Bear Case

    Bull case

    • 100.0% of OCUL's analyst ratings are Buy or Strong Buy.

    Bear case

    • OCUL beat EPS estimates in 25.0% of its last 8 reported quarters.

    OCUL Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -11.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.35
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 0 down

    Frequently Asked Questions About OCUL

    Does OCUL pay dividends?

    Ocular Therapeutix Inc (OCUL) does not currently pay a regular dividend.

    What is OCUL's market cap?

    Ocular Therapeutix Inc (OCUL) has a market capitalization of $1.58B with a current stock price of $7.38.

    Related stocks

    Sector: Healthcare

    All stocks starting with O

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In